Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年9月6日
	新闻
	Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug Mugglehead Investment Magazine Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug, which represents a significant development in cancer fighting. 标记为不相关
	Glenmark begins phase 3 trial of novel lung cancer drug Envafolimab - Healthcare Radius Healthcare Radius Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC comprising approximately 80 to 85 per cent of cases, and 20 ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈